DiffCof Chesty Cough Syrup Special Precautions

Patients being treated with DiffCof Chesty Cough Syrup should be notified of an expected increase in the flow of secretions.
There have been very rare reports of severe skin lesions such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (TEN) in temporal association with the administration of mucolytic substances such as bromhexine. Mostly, these could be explained by the severity of the patient's underlying disease and/or concomitant medication. In addition, during the early phase of a Stevens-Johnson syndrome or TEN a patient may first experience non-specific influenza-like prodromes like e.g. fever, aching body, rhinitis, cough and sore throat. Misled by these non-specific influenza-like prodromes it is possible that a symptomatic treatment is started with a cough and cold medication. Therefore, if new skin or mucosal lesions occur, medical advice should be sought immediately and treatment with bromhexine should be discontinued as a precaution.
DiffCof Chesty Cough Syrup contains sorbitol, which may have a laxative effect or can cause diarrhoea in some people.
Effects on the ability to drive and use machines: No studies on the effects on the ability to drive and use machines have been performed with DiffCof Chesty Cough Syrup.